By Topic

The translational value of the MPTP non-human primate model of Parkinsonism for deep brain stimulation research

Sign In

Cookies must be enabled to login.After enabling cookies , please use refresh or reload or ctrl+f5 on the browser for the login options.

Formats Non-Member Member
$33 $13
Learn how you can qualify for the best price for this item!
Become an IEEE Member or Subscribe to
IEEE Xplore for exclusive pricing!
close button

puzzle piece

IEEE membership options for an individual and IEEE Xplore subscriptions for an organization offer the most affordable access to essential journal articles, conference papers, standards, eBooks, and eLearning courses.

Learn more about:

IEEE membership

IEEE Xplore subscriptions

7 Author(s)
Peter A. Tass ; Institute of Neuroscience and Medicine-Neuromodulation, Research Centre Juelich, Germany and the Division for Neuromodulation, Medical School, University of Cologne, Germany ; Li Qin ; Christian Hauptmann ; Sandra Dovero
more authors

Deep brain stimulation (DBS) has been applied in more than 70000 patients worldwide during the last two decades. The main target is the subthalamic nucleus (STN) for the treatment of motor complications in late stage Parkinson's disease (PD). Positive results in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated non-human primates have set the grounds for its successful translation to PD patients. Since then, this model has allowed gaining significant insights in the underlying mechanisms of action of DBS and is currently being used for the development of new stimulation techniques. Altogether, this underpins the high potential of this preclinical model for future translation of DBS research in PD.

Published in:

2011 Annual International Conference of the IEEE Engineering in Medicine and Biology Society

Date of Conference:

Aug. 30 2011-Sept. 3 2011